BioInvent International AB

About Us

BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with four programs in clinical development. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com.

Contacts

BIOINVENT
Sölvegatan 41 223 70 LUND
+46 46 286 85 50
+46 46 211 08 06
http://www.bioinvent.com
info@bioinvent.com

Quotes

FDA approval of the Phase I/IIa study of BI-1808 is another important milestone for BioInvent as we continue to broaden our exciting pipeline of anti-cancer antibodies. TNFR2 is increasingly attracting interest as revealed by the recent deals in the field. The development of BI-1808 is supported by an impressive set of preclinical data and is one of three BioInvent lead candidates in clinical development.

Martin Welschof, CEO BioInvent International

The data on BI-1607 are very exciting and provide proof-of-concept of its ability to enhance anti-cancer immunity, illustrated by its ability to boost activity and overcome resistance to CTLA-4-based therapy. We are looking forward to advancing BI-1607 into clinical development and expect to submit a clinical trial application during H2 2021. It will be BioInvent’s fourth drug candidate in clinical development, further demonstrating the strength and productivity of our technology platform.

Martin Welschof, CEO

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

BioInvent granted US patent for the F.I.R.S.T.™ antibody screening technology

Mon, Nov 11, 2013 08:30 CET

Lund, Sweden – 11 November, 2013 – BioInvent International AB (OMXS: BINV) today announces that it has has been granted a US patent for its antibody and concomitant target discovery technology F.I.R.S.T.™. Traditional drug discovery methods involve the identification of drugs candidates that bind to known disease targets. The F.I.R.S.T.™ technology is a novel and unique discovery method, which allows for antibodies and disease targets to be identified simultaneously. BioInvent has used F.I.R.S.T.™ successfully in several proprietary discovery projects and offers F.I.R.S.T.™ as well as

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Contacts

Quotes

BioInvent granted US patent for the F.I.R.S.T.™ antibody screening technology

Subscribe